Clinical Trial Update: Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas [Phase 1]

View source ↗

Summary

A Phase 1 study of multiple intracerebral doses of NSC-CRAd-S-pk7 for recurrent high-grade gliomas (glioblastoma) is currently suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• NSC-CRAd-S-pk7

Snippet

Sponsor: City of Hope Medical Center | Conditions: Currently Only Enrolling Glioblastoma Patients at First Recurrence | Phase 1 | Status: SUSPENDED